BiotechTube
Empiriko

Empiriko

Cambridge, United States· Est.
empiriko.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Empiriko is a private, preclinical-stage biotech founded in 1993 and based in Cambridge, Massachusetts. The company is pioneering an integrated platform that combines a novel targeted drug delivery system (R*ECL-AI-M™) for radioligand and ADC therapies with a remote diagnostic monitoring device (PMF™). This dual-pronged approach aims to revolutionize personalized cancer treatment by enabling precise therapy delivery and at-home tracking of disease and drug response. Led by an experienced CEO and supported by a distinguished scientific advisory board, Empiriko is positioned at the convergence of targeted radiopharmaceuticals and digital health.

OncologyCardiovascular Disease

Technology Platform

Integrated platform featuring R*ECL-AI-M™ for targeted radioligand/ADC drug delivery using synthetic azamacrocycles, and the PMF™ point-of-care diagnostic device for real-time disease/drug monitoring. Supported by a proprietary Green Chemistry and AI/computational modeling platform.

Opportunities

The convergence of the rapidly expanding targeted radiopharmaceutical and ADC markets with the growing demand for remote patient monitoring creates a significant white-space opportunity.
Empiriko's integrated 'therapy + monitoring' model aligns perfectly with the shift towards value-based and personalized healthcare, offering a potential solution to improve outcomes and reduce systemic costs.

Risk Factors

The company faces high technical risk in developing two novel, complex platforms simultaneously and clinical risk in proving their safety and efficacy.
Financial and execution risk is significant due to the capital-intensive nature of dual drug/device development as a private entity.
It also operates in intensely competitive markets against large, well-resourced players.

Competitive Landscape

In therapeutics, Empiriko competes with major pharma (e.g., Novartis, AstraZeneca) and biotechs in the hotly contested radioligand and ADC spaces. In diagnostics, it faces competition from established medtech firms and numerous digital health startups developing remote monitoring solutions. Its unique integration of both fields is its primary differentiator.

More companies in Radiopharmaceuticals →More companies in United States →